Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
TerminatedNCT06068868
AbbVieAcute Myeloid Leukemia
Start: 2023-11-13End: 2025-02-25Updated: 2025-03-06